Intravenous dantrolene in a patient with myasthenia gravis

Abstract

We report a case in which dantrolene administered in a dose sufficient to provide prophylaxis for MH, was safely administered to a patient with generalized MG. The responses to dantrolene in our MG patient differed from those in healthy volunteers. Specifically, our patient was resistant to the twitch-depressant effects of dantrolene, but after 2-3 h demonstrated a significant decrease in fade ratio. While dantrolene may produce clinical improvement in rats with EAMG, further studies would be required to determine whether it has a similar effect in human MG.